Proinsulin peptide immunotherapy in type 1 diabetes:safety data of a first in new-onset type 1 diabetes phase 1b trial
Mohammad Alhadj Ali(Cardiff University), Colin M Dayan, Nicola Leech(Newcastle upon Tyne Hospitals NHS Foundation Trust), Rachel Stenson(Cardiff University), Deirdre A Kyne, Mark Peakman(Sanofi (France)), Laura Adams(Guy's and St Thomas' NHS Foundation Trust), Yuk-Fun; id_orcid 0000-0002-8518-8756 Liu(Diabetes Australia), Graham Clifford, Jake Powrie(Guy's and St Thomas' NHS Foundation Trust), Robert Andrews, Kate Green(University Hospitals Bristol NHS Foundation Trust)
Research Portal (King's College London)
September 1, 2015
Cited by 0
Related Papers
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
|Diabetes Care|2019|350
Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes
|Diabetes|2014|244
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes
|Science Translational Medicine|2017|215
Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated β-Cell Death
|Diabetes|2011|213
Hydrophobic CDR3 residues promote the development of self-reactive T cells
|Nature Immunology|2016|185